Home » Topics » BioWorld Science

BioWorld Science
RSS

PGC-1alpha as a novel therapeutic target in sickle cell disease

Jan. 2, 2020

Phase I data presented for ambrisentan in sickle cell disease

Jan. 2, 2020

Autolus presents phase I data from Amelia study of AUTO-3 in pediatric patients

Jan. 2, 2020

Metformin, explained

Jan. 2, 2020

Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation

Dec. 31, 2019

CTX-712: a novel promising CLK inhibitor for myeloid tumors

Dec. 31, 2019

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

Dec. 31, 2019

FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392

Dec. 31, 2019

Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers

Dec. 31, 2019

New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia

Dec. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...